INPPL1 and gastric cancer: SHIP2 has been demonstrated to inhibit AKT activation in HepG2 cells [7], while a low expression of SHIP2 enhances the PI3K–AKT signaling to promote cell proliferation and tumorigenesis in gastric cancer [8].